comparemela.com
  1. Home
  2. Live Updates
  3. Glmd - Breaking News

Latest Breaking News On - Glmd - Page 6 : comparemela.com

Galmed Pharmaceuticals (NASDAQ:GLMD) Earns Sell Rating from Analysts at StockNews com

StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Free Report) in a report released on Monday morning. The firm issued a sell rating on the biopharmaceutical company’s stock. Separately, Maxim Group upgraded shares of Galmed Pharmaceuticals from a hold rating to a buy rating in a research report on Monday, July 24th. Read […]

United kingdomMaxim groupGalmed pharmaceuticalsNews ratings for galmed pharmaceuticals dailyGalmed pharmaceuticals ltdMillennium managementCambridge investment research advisors incInstitutional trading of galmed pharmaceuticalsGalmed pharmaceuticals stock performanceGalmed pharmaceuticals company profileRaymond james financial services advisors incFree reportJames financial services advisorsInvestment research advisorsGet free reportPharmaceuticals ltd

StockNews com Begins Coverage on Galmed Pharmaceuticals (NASDAQ:GLMD)

StockNews.com began coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Free Report) in a research report report published on Sunday. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Separately, Maxim Group upgraded Galmed Pharmaceuticals from a hold rating to a buy rating in a research note on Monday, July 24th. Check Out […]

United kingdomCambridge investment research advisors incRaymond james financial services advisors incMaxim groupHedge funds weigh in on galmed pharmaceuticalsGalmed pharmaceuticals stock downGalmed pharmaceuticalsGalmed pharmaceuticals company profileMillennium managementNews ratings for galmed pharmaceuticals dailyGalmed pharmaceuticals ltdFree reportPharmaceuticals stock downGet free reportInvestment research advisorsRaymond james financial services advisors

Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated by Analysts at StockNews com

StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Free Report) in a report issued on Saturday. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Separately, Maxim Group upgraded Galmed Pharmaceuticals from a hold rating to a buy rating in a research note on Monday, July 24th. Get Our Latest Analysis […]

United kingdomRaymond james financial services advisors incMaxim groupCambridge investment research advisors incNews ratings for galmed pharmaceuticals dailyGalmed pharmaceuticals stock performanceGalmed pharmaceuticals ltdMillennium managementGalmed pharmaceuticalsFree reportGet free reportJames financial services advisorsCambridge investment research advisorsPharmaceuticals ltdGalmed pharmaceuticals dailyNasdaq glmd

Galmed Pharmaceuticals (GLMD) – Analysts Recent Ratings Changes

Several analysts have recently updated their ratings and price targets for Galmed Pharmaceuticals (NASDAQ: GLMD): 8/12/2023 – Galmed Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock. 8/4/2023 – Galmed Pharmaceuticals is now covered by analysts at StockNews.com. They set a “sell” rating on the stock. 7/27/2023 – […]

United kingdomHedge funds weigh in on galmed pharmaceuticalsCambridge investment research advisors incGalmed pharmaceuticals ltdGalmed pharmaceuticals tradingMaxim groupRaymond james financial services advisors incGalmed pharmaceuticalsNews ratings for galmed pharmaceuticals ltd dailyMillennium managementGet free reportJames financial services advisorsCambridge investment research advisorsPharmaceuticals ltdGalmed pharmaceuticals ltd dailyNasdaq glmd

Galmed Pharmaceuticals (NASDAQ:GLMD) Receives New Coverage from Analysts at StockNews com

StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Free Report) in a research report sent to investors on Saturday. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Separately, Maxim Group raised shares of Galmed Pharmaceuticals from a hold rating to a buy rating in a report on Monday, July 24th. […]

United kingdomGalmed pharmaceuticals company profileMillennium managementRaymond james financial services advisors incCambridge investment research advisors incNews ratings for galmed pharmaceuticals dailyGalmed pharmaceuticals ltdGalmed pharmaceuticals price performanceGalmed pharmaceuticalsMaxim groupInstitutional investors weigh in on galmed pharmaceuticalsFree reportGet free reportInvestment research advisorsRaymond james financial services advisorsJames financial services advisors

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.